Clinical Trial

A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

Study acronym: ZAPPHIRE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis (IPF). It is a phase IIb, multicentre, randomised, double-blind, placebo-controlled, three-arm parallel-group study. A total of 240 participants with IPF (Idiomatic Pulmonary Fibrosis) will be randomised in approximately 150 investigational sites in North and Latin America, Europe, Asia, and Oceania.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-17
Trial Details
NCT Number NCT07516951
Lead Sponsor Chiesi Farmaceutici S.p.A.
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 240 participants
Start Date 2026-07-08
Primary Completion 2028-02-12 (estimated)
Study Completion 2028-02-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-16